CLAIMS

1. Use of a nerve growth factor (NGF) antagonist in the manufacture of a medicament for treating bone cancer pain in an individual.

2. The use of claim 1, wherein the bone cancer pain is from cancer originated in bone.

3. The use of claim 2, wherein the bone cancer pain is from osteosarcoma.

4. The method of claim 1, wherein the bone cancer pain is from cancer metastasized to bone.

5. The use of claim 4, wherein the cancer metastasized to bone is selected from prostate cancer, breast cancer, lung cancer, sarcoma, and renal cancer.

6. The use according to any one of the preceding claims, wherein the NGF antagonist is an anti-NGF antagonist antibody.

7. The use of claim 6, wherein the anti-NGF antagonist antibody is a monoclonal antibody.

8. The use of claim 6, wherein the anti-NGF antagonist antibody is a humanized antibody.

9. The use of claim 6, wherein the anti-NGF antagonist antibody is a human antibody.

10. The use of any one of claims 6 to 9, wherein the anti-NGF antagonist antibody binds human NGF.

11. The use of claim 10, wherein the anti-NGF antagonist antibody further binds rodent NGF.

12. The use of claim 10, wherein the anti-NGF antagonist antibody binds human NGF with a K_D of about 0.1 nM or less than about 0.1 nM.

13. The use of claim 6, wherein the heavy chain variable region of the anti-NGF antagonist antibody comprises the amino acid sequence shown in SEQ ID NO: 1.

14. The use of claim 6 or claim 13, wherein the light chain variable region of the anti-NGF antagonist antibody comprises the amino acid sequence shown in SEQ ID NO: 2.

15. The use of any one of the preceding claims, wherein the NGF-antagonist is not for co-administration with an opioid analgesic.

16. A kit for treating bone cancer pain comprising an NGF antagonist, and instructions for using the NGF antagonist to treat bone cancer pain.

Claims

1. Use of a nerve growth factor (NGF) antagonist in the manufacture of a medicament for treating bone cancer pain in an individual, wherein the NGF antagonist is an anti-NGF antagonist antibody.

2. The use of claim 1, wherein the bone cancer pain is from cancer originated in bone.

3. The use of claim 2, wherein the bone cancer pain is from osteosarcoma.

4. The use of claim 1, wherein the bone cancer pain is from cancer metastasized to bone.

5. The use of claim 4, wherein the cancer metastasized to bone is selected from prostate cancer, breast cancer, lung cancer, sarcoma, and renal cancer.

6. The use of any one of the preceding claims, wherein the anti-NGF antagonist antibody is a monoclonal antibody.

7. The use of any one of claims 1 to 5, wherein the anti-NGF antagonist antibody is a humanized antibody.

8. The use of any one of claims 1 to 5, wherein the anti-NGF antagonist antibody is a human antibody.

9. The use of any one of the preceding claims, wherein the anti-NGF antagonist antibody binds human NGF.

10. The use of claim 9, wherein the anti-NGF antagonist antibody further binds rodent NGF.

11. The use of claim 9, wherein the anti-NGF antagonist antibody binds human NGF with a KD of about 0.1 nM or less than about 0.1 nM.

12. The use of any one of claims 1 to 5 or 7, or of any one of claims 9 to 11 when dependent on any one of claims 1 to 5 or 7, wherein the heavy chain variable region of the anti-NGF antagonist antibody comprises the amino acid sequence shown in SEQ ID NO:1.

13. The use of any one of claims 1 to 5, 7 or 12, or of any one of claims 9 to 11 when dependent on any one of claims 1 to 5 or 7, wherein the light chain variable region of the anti-NGF antagonist antibody comprises the amino acid sequence shown in SEQ ID NO:2.

14. The use of any one of the preceding claims, wherein the NGF-antagonist is not for co administration with an opioid analgesic.

15. An anti-NGF antagonist antibody for use in treating bone cancer pain in an individual.